Autolus Therapeutics (NASDAQ:AUTL) Shares Down 4.6% – What’s Next?

Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price dropped 4.6% during mid-day trading on Wednesday . The stock traded as low as $4.07 and last traded at $4.14. Approximately 194,190 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 1,339,275 shares. The stock had previously closed at $4.34.

Autolus Therapeutics Stock Performance

The business’s 50 day moving average price is $4.04 and its 200-day moving average price is $4.07. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.55 and a current ratio of 18.55.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). Equities research analysts predict that Autolus Therapeutics plc will post -0.84 EPS for the current fiscal year.

Institutional Trading of Autolus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Avoro Capital Advisors LLC purchased a new position in Autolus Therapeutics in the first quarter valued at about $78,765,000. Price T Rowe Associates Inc. MD increased its holdings in Autolus Therapeutics by 82.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after purchasing an additional 2,487,778 shares during the last quarter. Great Point Partners LLC raised its position in shares of Autolus Therapeutics by 195.0% in the 2nd quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock valued at $11,977,000 after purchasing an additional 2,275,000 shares in the last quarter. Affinity Asset Advisors LLC boosted its stake in shares of Autolus Therapeutics by 117.7% during the 1st quarter. Affinity Asset Advisors LLC now owns 3,375,000 shares of the company’s stock valued at $21,532,000 after buying an additional 1,824,592 shares during the last quarter. Finally, Armistice Capital LLC grew its position in shares of Autolus Therapeutics by 33.8% during the second quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock worth $21,750,000 after buying an additional 1,578,000 shares in the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.